Atlas Trials

Rollover Study for Continued Safety and Tolerability in Subjects Treated With Spartalizumab Alone or in Combination With Other Study Treatments

Clinical trial NCT04058756 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT04058756
Sponsor
Novartis Pharmaceuticals
Status
ACTIVE_NOT_RECRUITING
Phase
Phase 1
Study type
INTERVENTIONAL
Advanced Solid Tumors
Start date
2019-10-30
Primary completion
2030-04-30
Enrollment
120

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.